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Many of the inflammatory pathways regulating the production of prostanoids are implicated in the development of colon cancer. Diets rich in
fruits and vegetables are associated with decreased rates of colon cancer and this may reflect anti-inflammatory properties of some phytochemicals
in plant-based foods. In order to ascertain which of the many dietary compounds may be protective, a cell-based screening method was established
to determine their effects on the production of prostanoids. By up-regulating prostaglandin H synthase-2 in human colonic fibroblast cells with
cytokines, we have investigated the potential protective effect of a structurally related group of phytochemicals on prostanoid biogenesis. Several
of the compounds significantly inhibited prostanoid biogenesis, by up to 81% and others enhanced prostanoid production. All of the compounds
that enhanced prostanoid production belonged to the hydroxylated benzoic acid family and good correlation was observed with their redox activity
and the ability to enhance prostanoid production. Common structural features of the inhibitors were the presence of 4-hydroxyl and 3-methoxyl
substituents on the aromatic ring and/or the presence of a three-carbon side-chain on C1.
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Colon cancer is the fourth most common malignancy in the
world [1]. Carcinogenic progression in previously normal
colonic mucosa involves hyperproliferation and adenoma
formation. The mechanism by which some adenomas undergo
malignant transformation is not fully understood. However, up-
regulation of inflammatory markers such as NF-nB [2],
phospholipase A2 [3] and the inducible form of prostaglandin
H synthase (PGHS-2) [4] suggest that prostanoid production is
a key event in the carcinogenic process. Consequently,
chemopreventive strategies to inhibit development and induce
regression of colorectal adenomas often involve modulation of
the pathways regulating PGHS-2. The effective use of the non-
steroidal anti-inflammatory drugs (NSAIDs) and the so called
Fcyclooxygenase inhibitors_ to regress existing colorectal
adenomas has also been demonstrated [5,6]. However, the
use of these drugs is sometimes associated with significant
morbidity and even mortality [7] and therefore, there is a need0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.08.007
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E-mail address: W.Russell@rowett.ac.uk (W.R. Russell).to develop alternative strategies to decrease disease risk.
Regular consumption of fruit and vegetables is known to
decrease the risk of developing colon cancer [8]. Many of the
phytochemicals present in fruits and vegetables and in
particular those produced by the phenylpropanoid pathway
are similar in structure to therapeutic drugs. It is possible that
they are responsible, in part, for the anti-cancer properties of
diets rich in fruits and vegetables.
Prostanoids (which include the prostaglandins and throm-
boxanes) are endogenous mediators of tissue inflammation.
PGHS is the key enzyme involved in the biosynthesis of
prostanoids and the PGHS-2 isoform has been recognised as
being primarily responsible for the synthesis of prostanoids
involved in pathological processes. Although up-regulated
PGHS-2 and increased prostanoid synthesis are implicated in
the early stages of colorectal neoplasia, its expression is barely
detectable in normal and premalignant colorectal epithelium
and is probably confined to subepithelial cells, such as
fibroblasts [9]. These colonic fibroblasts are potentially
important targets, as cytokine induction results in a significant
increase of PGHS-2 without altering PGHS-1 expression [10].
The aims of this study were to develop a screening assay to1762 (2006) 124 – 130
http://www
W.R. Russell et al. / Biochimica et Biophysica Acta 1762 (2006) 124–130 125assess the ability of a structurally related group of phytochem-
icals (Table 1) to inhibit prostanoid biogenesis in human colonic
fibroblast cells following cytokine-induced PGHS-2 up-regula-
tion. Products of the phenylpropanoid pathway were selected
for study, as this pathway produces the largest range of natural
products considered potentially protective of health. The
cinnamic and benzoic acids and their derivatives were the main
focus of this study. These compounds are major components of
the diet and, as well as being bioavailable in the colon, are the
metabolites of many of the higher molecular weight phenolic
compounds. Identification of plant compounds, which modulate
prostanoid production will then allow the rational selection of
candidate phytochemicals for further studies in intervention
trials with human subjects and allow more effective dietary
advice to decrease the risk of colon cancer.
2. Materials and methods
2.1. Reagents
Compounds 1b, 1d–g, 1i, 3–5 and 8a–d were obtained from Aldrich
[Gillingham, England], compounds 1a, 1j, 2 and 8e were obtained from Sigma
[Poole, England] and compounds 1 h and 6 were obtained from Fluka
[Gillingham, England]. Compound 12 was obtained from Alexis [Bingham,
England] and compounds 8 f, 10 and 11 were synthesised as reported
previously [11,12]. Interleukin-1h (IL-1h), Tumour Necrosis Factor-a (TNF-
a), Dulbecco’s modified eagles medium and the antibiotic/antimycotic solution
were obtained from Sigma [Poole, England]. Fetal bovine serum (FBS) was
obtained from Hyclone [Logan, UT] and SC-560 and DuP-697 were obtained
from Cayman Chemicals [Ann Arbor, MI].
2.2. Cell culture
Human colonic fibroblast cells CCD-18Co (CRL-1459) were obtained from
the American Type Culture Collection [Middlesex, England]. Prior to
performing the experiments, cells were maintained in medium containing
FBS (10% v/v) and an antibiotic/antimycotic (1% v/v). Cells were purchased at
a population doubling (PDL) of 22 and all studies were performed on cells from
the third (PDL 23) to fifth passage (PDL 27) in culture and the cells were
allowed to grow to approximately 75% confluence before being passaged.
2.3. Up-regulation and western analysis of PGHS-2
Fibroblasts cells were seeded at a density 3.5105 cell cm3 in media (10
cm3) supplemented with fetal bovine serum (10% v/v) and incubated for 24 h.
Media was replaced with serum-free media and the cells incubated for a further
two h. The cells were then treated with IL-1h (0.05 cm3) in PBS (0.05 cm3)
containing BSA (0.1% v/v) to give a final concentration of 10 ng cm3 or TNF-
a (0.05 cm3) in PBS (0.05 cm3) containing BSA (0.1% v/v) to give a final
concentration of 50 ng cm3. Control cells were treated with PBS (0.05 cm3)
containing BSA (0.1% v/v). Media was removed and cells washed and then
harvested with sucrose (150 mmol dm3) in Tris–HCl (10 mmol dm3; pH
7.4). Protein extracts were prepared by incubating the cells with ice-cold Tris–
HCl buffer (20 mmol dm3; pH 7.4) containing NaCl (150 mmol dm3), EDTA
(5 mmol dm3), Na3VO4 (0.1 mmol dm
3), leupeptin (4 mg cm3), a-
toluenesulphonyl fluoride (60 Ag cm3) and Triton X-100 (0.1% v/v) on ice for
thirty min with intermittent (5 min) agitation using a vortexer. Protein content
in the supernatants was measured using the Bio-Rad protein assay [Bio-Rad
Laboratories; Hemel Hempstead, England], which is based on the Bradford
method [13] and samples (62 Ag protein) were subjected to gel electrophoresis
(10% Acrylamide/Bis 37.5:1) [Bio-Rad Laboratories; Hemel Hempstead,
England]. After separation, the proteins were transferred to a membrane and
incubated for 30 min with a primary PGHS-2 specific antibody [Abcam;
Cambridge, England] diluted at to a concentration 1:5000. Bound antibodieswere detected by chemiluminescence [Supersignal\ West Pico; Pierce; Rock-
ford, IL] and the resulting bands analysed by densitometry.
2.4. Cell viability assay
The number of viable cells was measured using a colorimetric assay
[CellTiter96\AQueous; Promega; Madison, WI] where 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenol)-2H-tetrazolium salt is
reduced by the cells into a coloured formazan product.
2.5. Measurement of prostanoids produced
As serum is a potent inducer of prostanoids it was removed prior to
measuring the concentration of prostanoids produced. Fibroblast cells were
seeded at a density 2500, 5000 and 10,000 well1 in a 96-well cell culture plate
in media (0.1 cm3) supplemented with fetal bovine serum (10% v/v) and
incubated for 24 h. To test the effect of serum removal, cells were washed and
then incubated in serum-free media for a further 1.5 h. This slightly decreased
the number of viable cells but the response remained linear (r2=0.9908) up to
10000 cells per well. At this time (30 min prior to stimulation), DMSO (diluted
1:400 with media; 0.01 cm3) was added, as this was the solvent in which the
phytochemicals were dissolved. After thirty min IL-1h and TNF-a (diluted
1:100 with media; 0.01 cm3) were added to give concentrations of 10 ng cm3
and 50 ng cm3, respectively. The solvent (DMSO) and reagents (IL-1h and
TNF-a) required for the assay had no effect on viable cell number
(0.9839 r20.9953). For the prostanoid assay, fibroblast cells at P3–P5
(PDL 23–27) were seeded at a density 1104 well1 in a 96-well cell culture
plate and treated with solvents and cytokines as described above. At the end of
the 2-h stimulation period, aliquots were removed and screened with a
prostaglandin screening EIA [Cayman Chemicals; Ann Arbor, MI] designed to
measure a wide range of prostanoids. Samples were appropriately diluted and
immediately assayed according to the manufacturer’s instructions.
2.6. Treatment with specific inhibitors and phytochemicals
Thirty minutes prior to cytokine stimulation, the specific PGHS inhibitors
and selected phytochemicals were added. The compounds were dissolved in
DMSO diluted 1:400 with media and added (0.01 cm3) to give final
concentrations of 0.01, 0.1 and 1.0 Amol dm3 for the specific inhibitors and
0.1 Amol dm3 for the phytochemicals. The cell culture conditions and
measurement of prostanoids produced was as described above.
2.7. Electron paramagnetic resonance spectroscopy
Aliquots (3 cm3) of galvinoxyl (0.5 mmol dm3 in methanol) were mixed
with substrates (measured at various concentrations to determine linearity,
typically 0.1–0.5 mmol dm3 in methanol) and transferred to an EPR quartz
cell. Spectra (X-band) of unreacted galvinoxyl were recorded after 5 min on a
Bruker E106 spectrometer, equipped with a TM110 cavity. The following
instrument settings were used: modulation frequency 100 kHz; centre field
3480.40 Gauss; sweep width 60 Gauss; time constant 40.96 ms; power, 1.01
mW and a suitable receiver gain setting, typically 1104. The galvinoxyl
concentrations remaining were calculated by integration of the signal and
comparison with the control. From these concentrations, the stoichiometry of
the reaction was calculated.
2.8. Computational modelling
The structural co-ordinates of the crystal structure of arachidonic acid
bound to the active site of PGHS-2 was downloaded from the Brookhaven
Protein Database [14]. Using the Cerius2 ligand fit package [Accelrys;
Cambridge, England] running on an SGI Octane workstation, the protein and
ligand were defined and a binding site generated with a resolution of 0.5 A˚ and
hydrogen and heavy atom radii of 2 A˚ and 2.5 A˚, respectively. Energy
minimised structures of the compounds were then selected as potential ligands
and were fitted and scored using ligand Monte Carlo parameters with polar
hydrogens set at 30- and RMS and score thresholds of 1.5 and 20, respectively.
Table 1
Phytochemical IUPAC names and synonyms with R group specification
Compounds 1a, 1c, 1f, 1h, 1j, 2, 8d, 8e, 9a and 9b are found ubiquitously in many plant foods.
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Fig. 1. (A) Up-regulation of PGHS-2 detected by Western blotting after 2-
h incubation with IL-1h (10 ng cm3) and TNF-a (50 ng cm3). The PGHS-2
standard as shown here was loaded at 10 ng and was determined to be linear up
to 20 ng (r2=0.975). All measurements were made within this range and the
results are representative of three independent experiments. (B) Graphical
representation of the densitometry measurements. Values represent the mean
and standard deviation of three separate experiments and significant differences
were determined by the TTEST.
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interaction potential energy was selected.
3. Results
Treatment with cytokines resulted in an approximate six-
fold up-regulation of PGHS-2 by IL-1h and twelve-fold up-
regulation of PGHS-2 by TNF-a (Fig. 1). Stimulation in
serum-free conditions resulted in an increase in prostanoid
concentrations from 1.23T0.14 ng cm3 to 10.26T1.20 ng
cm3 (P <0.001) and 9.50T0.88 ng cm3 (P <0.001) with IL-
1h and TNF-a respectively. To determine assay selectivity and
dose response, cells were treated with specific PGHS inhibitors
(Fig. 2). SC-560, a selective PGHS-1 inhibitor has reportedFig. 2. Structures of selecIC50 values of 9 nmol dm
3 for PGHS-1 and 6.3 Amol dm3
for PGHS-2 and the selective PGHS-2 inhibitor, DuP-697 has
reported IC50 values of 9 Amol dm3 for PGHS-1 and 40–80
nmol dm3 for PGHS-2. Treatment of cells with these selective
inhibitors at final concentrations of 0.01, 0.1 and 1 Amol dm3
gave a dose-dependent increase in inhibition of PGHS-2 with
SC-560, whereas DuP-697 inhibited further prostanoid pro-
duction at all three concentrations (Fig. 3).
Twenty-eight compounds were selected for study, all of
which were derived via the phenylpropanoid pathway and
varied in substitution pattern, side-chain length and functional
group (Table 1). Many of these compounds are found in fruits,
vegetables, beverages and cereals and are a main component of
our diet. Sixteen compounds significantly inhibited prostanoid
production and two significantly enhanced the production of
prostanoids (Table 2). There was a strong structure–activity
relationship. Compounds that had little inhibitory effect or
enhanced prostanoid production were hydroxylated benzoic
acids (Table 1; compounds 1a–j). Compounds inhibiting
prostanoid production had a 4-hydroxy-3-methoxy aromatic
substitution pattern or were cinnamic acids. Both the unstimu-
lated and stimulated cells treated with phytochemicals were
between 92 and 123% viable at the end of the experiment.
Compounds can enhance or inhibit prostanoid biogenesis by
affecting the signaling pathways leading to the production of
PGHS-2 [6] or by directly affecting the catalytic activity of
PGHS-2 [15]. Their ability to inhibit or enhance PGHS-2
activity requires consideration of both the cyclooxygenase and
peroxidase activities of the enzyme [16]. The potential
structural binding of PGHS inhibitors to the cyclooxygenase
active site can be investigated by computational chemistry
[17–19]. Three specific PGHS-2 inhibitors; DuP-697, Cel-
ecoxib and CAY-10404 (Fig. 2) were selected to assess the
computational modeling and gave binding scores to the PGHS-
2 cyclooxygenase active site of 62.27, 52.90 and 46.25,
respectively. The test compounds were then screened to see
how they compared to these values. Similarly, with the
exception of 4-hydroxy-3-methoxybenzaldehyde (Table 1,
compound 4), the compounds which inhibited prostanoid
production fitted the active site and gave scores between
33.02 and 69.21 (Table 2). Those that enhanced or had little
effect on prostanoid production (hydroxylated benzoic acids;
Table 1; compounds 1a–j) did not fit the cyclooxygenase
active site (Table 2).tive PGHS inhibitors.
Fig. 3. Dose-dependent effect of the selective PGHS-1 inhibitor, SC-560 and the selective PGHS-2 inhibitor, DuP-697 on prostanoid production after 2 h stimulation
with IL-1h (10 ng cm3). Data as meanT standard deviations (n =3). Significant differences were determined by the TTEST (***P <0.01, **P <0.05) with reference
to the IL-1h-stimulated cells (a).
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suring the extent by which the compounds reduced the
synthetic radical galvinoxyl [20] were generated to assess
potential redox effects on peroxidase activity. Ability to act as a
reductant increased with increasing ability to enhance prosta-
noid production. With the exception of the two least effective
inhibitors having the highest reducing equivalents, there was
no relationship between ability to inhibit prostanoid production
and the redox chemistry of the compounds (Table 1).Table 2
Effect of phytochemicals (1–12) on prostanoid production after two h stimulation w
passage 5; population doubling 27 (P5)
CellsTStimulant Compound Prostanoids (ng cm3) Enhancement
P4 3.26T0.50
P4+IL-1h 4.92T2.34
P5 16.59T6.45
P5+IL-1h 24.28T7.73
P4+IL-1h 1a 5.95T1.40 20.93
P4+IL-1h 1b 4.27T0.27 13.21
P4+IL-1h 1c 4.86T0.75 1.22
P4+IL-1h 1d 6.30T2.05 28.05
P4+IL-1h 1e 8.63T2.50 75.41
P4+IL-1h 1f 9.83T1.51 99.80
P4+IL-1h 1g 9.19T2.11 86.79
P4+IL-1h 1h 9.72T0.68 97.56
P4+IL-1h 1i 8.87T1.95 80.28
P4+IL-1h 1j 11.02T0.59 123.98
P5+IL-1h 2 11.39T5.23 53.09
P5+IL-1h 3 5.62T2.83 76.85
P5+IL-1h 4 4.52T0.93 81.38
P5+IL-1h 5 8.16T2.27 66.39
P5+IL-1h 6 5.96T1.85 75.45
P5+IL-1h 7 7.84T4.87 67.71
P5+IL-1h 8a 8.06T0.72 66.80
P5+IL-1h 8b 8.37T1.87 65.53
P5+IL-1h 8c 8.23T4.25 66.10
P5+IL-1h 8d 6.40T1.22 73.64
P5+IL-1h 8e 14.97T5.10 38.34
P5+IL-1h 8f 9.18T1.49 62.19
P5+IL-1h 9a 11.84T0.40 51.24
P5+IL-1h 9b 7.22T2.85 70.26
P5+IL-1h 10 6.39T4.28 73.68
P5+IL-1h 11 6.06T5.91 75.04
P5+IL-1h 12 15.27T2.91 37.11
Reducing equivalents are given as reaction stoichiometries for galvinoxyl radical re
scores. Values are given as meanT standard deviations (n =3). Significant difference
of phytochemicals were determined by the TTEST and are marked as ***P <0.01,4. Discussion
In agreement with previous studies [9,10], treatment of
human fibroblast cells with cytokines (IL-1h and TNF-a)
resulted in an up-regulation of PGHS-2 and increased
prostanoid biogenesis. Treatment with a specific PGHS-2
inhibitor (DuP-697) fully decreased the concentration of
prostanoids produced. The sensitivity of the system was further
emphasised by treatment with a specific PGHS-1 inhibitor (SC-ith IL-1h (10 ng cm3) in cells at passage 4; population doubling 25 (P4) and
/inhibition (%) P Reducing equivalent PGHS-2 binding fit
NS none no fit
NS none no fit
NS none no fit
NS 1.41T0.03 no fit
* none no fit
** 1.50T0.03 no fit
* 0.80T0.03 no fit
* 1.30T0.11 no fit
* none no fit
** 2.13T0.04 no fit
*** none 33.02
*** none 34.24
*** none no fit
*** 0.60T0.04 31.78
*** none 37.13
*** 0.79T0.06 37.32
*** none 35.80
*** none 35.78
*** none 37.92
*** none 35.37
* 1.47T0.05 38.54
*** 1.69T0.02 35.82
*** 1.37T0.05 40.90
*** 1.67T0.06 46.11
*** 0.31T0.01 49.96
*** 1.49T0.10 38.82
** 1.75T0.28 69.21
duction. Structural fit to the cyclooxygenase active site of PGHS-2 is given as
s between the IL-1h-stimulated cells and IL-1h-stimulated cells in the presence
**P <0.05, *P <0.1 and NS=not significant.
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noid production which reflected the reported IC50 of this
compound for PGHS-2. Treatment with a group of twenty-
eight phenylpropanoid-derived phytochemicals resulted in a
wide range of effects from 81% inhibition to 123% enhance-
ment of prostanoid production (Table 1).
Those compounds that enhanced prostanoid production all
belonged to the hydroxylated benzoic acid family (Table 1).
These C6C1 compounds had a poor structural fit to the PGHS-
2, cyclooxygenase active site. The trihydroxylated benzoic acid
enhanced prostanoid production more than the dihydroxylated
compounds and these in turn had a greater effect on enhancing
prostanoid production than the mono-hydroxylated benzoic
acids. The stoichiometric reducing equivalents for those
compounds that significantly enhanced prostanoid production,
indicates that their mode of action could be due to their redox
chemistry. This is further emphasised by their poor structural fit
to the cyclooxygenase active site suggesting that they could be
enhancing prostanoid production by effecting the redox
chemistry of the peroxidase component of PGHS-2. However,
it is also possible that these compounds may be effecting the
signaling pathways leading to the up-regulation of PGHS-2.
Of the compounds that significantly inhibited prostanoid
production, two structural features appeared to be of impor-
tance; the presence of a 4-hydroxyl and 3-methoxyl substituent
on the aromatic ring and/or the presence of a three-carbon side-
chain on C1. Compounds that had both of these features were
very good fits to the PGHS-2 cyclooxygenase active site, with
binding scores between 38.82 and 69.21. The compounds that
contained the C3 side-chain, but lacked the 4-hydroxy-3-
methoxy substitution pattern also had reasonably good fits to
the cyclooxygenase active site with binding scores between
35.37 and 38.34. However, the compound that had the greatest
effect on inhibition of prostanoid production, was 4-hydroxy-3-
methoxybenzaldehyde (Table 1; compound 4) and this did not
fit the cyclooxygenase active site. It contains the 4-hydroxyl
and 3-methoxyl substituents, but does not have a three-carbon
side chain on C1. The next three inhibitors that have the
poorest fits to the cyclooxygenase active site (Table 1;
compounds 2, 3 and 5) also have 4-hydroxy-3-methoxy
substitution, but no three-carbon side chain on C1. Compounds
with this substitution pattern, which do not have a good
structural fit to the active site of cylooxygenase may more
likely be effecting the signaling pathways leading to the up-
regulation of PGHS-2, than directly affecting the activity of
PGHS-2.
It is without doubt that the up-regulation of PGHS-2 is
associated with the development of certain cancers. We have
shown that compounds present in fruits and vegetables can
decrease prostanoid biogenesis when PGHS-2 is induced.
Whether consumption of products rich in these compounds
may be beneficial to health will remain unclear until their
bioavailability is fully assessed. However, in light of recent
speculation for the safety of therapeutics that specifically
inhibit PGHS-2 [21,22], it may also be necessary to look
towards compounds present in the diet as potential chemopre-
ventives [23,24]. Because of this, the necessity to understandtheir mechanism of action becomes ever more important.
Identifying compounds that significantly inhibit or enhance the
overall production of prostanoids provides ideal candidates for
further studies to elucidate their direct mechanism of action. It
also highlights potential compounds and foods that contain
these compounds for use in colorectal cancer chemoprevention
studies.
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